Phase II study of biweekly cetuximab plus mFOLFOX6 or mFOLFIRI as second-line treatment for metastatic colorectal cancer and exploratory analysis of associations between DNA methylation status and the efficacy of the anti-EGFR antibody: T-CORE1201
T-CORE1201：一项II期研究，评估每两周一次的西妥昔单抗联合mFOLFOX6或mFOLFIRI方案作为转移性结直肠癌二线治疗方案的疗效，并探索DNA甲基化状态与抗EGFR抗体疗效之间的关联。
期刊:Journal of Gastrointestinal Oncology
影响因子:2
doi:10.21037/jgo-22-862
Takahashi, Shin; Ouchi, Kota; Sakamoto, Yasuhiro; Mori, Takahiro; Shimodaira, Hideki; Takahashi, Masahiro; Ohori, Hisatsugu; Kudo, Chieko; Takahashi, Yoshikazu; Imai, Hiroo; Akiyama, Shoko; Takahashi, Masanobu; Suto, Takeshi; Murakawa, Yasuko; Oishi, Takayuki; Isobe, Hideki; Okada, Yoshinari; Kawai, Sadayuki; Yoshioka, Takashi; Sato, Toshihiko; Shindo, Yoshiaki; Sugiyama, Shunsuke; Komine, Keigo; Chiba, Natsuko; Okita, Akira; Yamaguchi, Takuhiro; Ishioka, Chikashi
肿瘤
肠癌
表观遗传
肿瘤免疫
DNA甲基化
EGF
EGFR
